The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children

Pediatric Obesity

Volumn 10, Issue 3, 2015, Pages 226-233

  Kazankov, K ^a   Moller H J ^a   Lange, A ^a   Birkebaek N H ^a   Holland Fischer, P ^a   Solvig, J ^a   Horlyck A ^a   Kristensen, K ^a   Rittig, S ^a   Handberg, A ^b   Vilstrup, H ^a   Gronbaek H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CD163; childhood obesity; macrophages; non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CD163 ANTIGEN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOLUBLE CD163 ANTIGEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BODY COMPOSITION; BODY WEIGHT; CHILD; CHILDHOOD OBESITY; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FIBROSIS; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; WEIGHT GAIN; ADOLESCENT; BEHAVIOR THERAPY; BLOOD; CALORIC RESTRICTION; DENMARK; LIFESTYLE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PEDIATRIC OBESITY; RISK REDUCTION; WEIGHT REDUCTION;

ADOLESCENT; ALANINE TRANSAMINASE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BEHAVIOR THERAPY; BIOMARKERS; C-REACTIVE PROTEIN; CALORIC RESTRICTION; CHILD; CHOLESTEROL, HDL; DENMARK; FEMALE; HUMANS; LIFE STYLE; MACROPHAGE ACTIVATION; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PEDIATRIC OBESITY; RECEPTORS, CELL SURFACE; RISK REDUCTION BEHAVIOR; WEIGHT LOSS;

EID: 84928927011     PISSN: 20476302     EISSN: 20476310     Source Type: Journal    
DOI: 10.1111/ijpo.252     Document Type: Article

References (30)

1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
2. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE,. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500-505.
3. Tilg H, Moschen AR,. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846.
4. Baffy G,. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009; 51: 212-223.
5. Moestrup SK, Moller HJ,. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med 2004; 36: 347-354.
6. Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK,. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. Eur J Haematol 2004; 72: 135-139.
7. Weaver LK, Hintz-Goldstein KA, Pioli PA, et al. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 2006; 80: 26-35.
8. Gronbaek H, Sandahl TD, Mortensen C, Vilstrup H, Moller HJ, Moller S,. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther 2012; 36: 173-180.
9. Holland-Fischer P, Gronbaek H, Sandahl TD, et al. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut 2011; 60: 1389-1393.
10. Waidmann O, Brunner F, Herrmann E, Zeuzem S, Piiper A, Kronenberger B,. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. J Hepatol 2013; 58: 956-961.
11. Rode A, Nicoll A, Moller HJ, et al. Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. Gut 2013; 62: 1231-1232.
12. Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A,. Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 2011; 57: 291-297.
13. Parkner T, Sorensen LP, Nielsen AR, et al. Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia 2012; 55: 1856-1862.
14. De Vito R, Alisi A, Masotti A, et al. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med 2012; 30: 49-56.
15. Gronbaek H, Lange A, Birkebaek NH, et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr 2012; 54: 223-228.
16. Birkebaek NH, Lange A, Holland-Fischer P, et al. Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children. Eur J Endocrinol 2010; 163: 895-900.
17. Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J,. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations. Metabolism 1979; 28: 1086-1096.
18. Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G,. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med 2009; 7: 21.
19. Moller HJ, Hald K, Moestrup SK,. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 2002; 62: 293-299.
20. Moller HJ, Nielsen MJ, Bartram J, et al. Soluble CD163 levels in children with sickle cell disease. Br J Haematol 2011; 153: 105-110.
21. Carolan E, Hogan AE, Corrigan M, et al. The impact of childhood obesity on inflammation, innate immune cell frequency and metabolic microRNA expression. J Clin Endocrinol Metab 2014; 99: E474-E478.
22. Volovelsky O, Weiss R,. Fatty liver disease in obese children-relation to other metabolic risk factors. Int J Pediatr Obes 2011; 6 (Suppl. 1): 59-64.
23. Nobili V, Bedogni G, Berni CR, et al. The potential role of fatty liver in paediatric metabolic syndrome: a distinct phenotype with high metabolic risk? Pediatr Obes 2012; 7: e75-e80.
24. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C,. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115: e500-e503.
25. Fjeldborg K, Christiansen T, Bennetzen M, Moller J, Pedersen SB, Richelsen B,. The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss. Obesity 2013; 21: 2437-2443.
26. Chawla A, Nguyen KD, Goh YP,. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011; 11: 738-749.
27. Tam CS, Clement K, Baur LA, Tordjman J,. Obesity and low-grade inflammation: a paediatric perspective. Obes Rev 2010; 11: 118-126.
28. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE,. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009; 50: 1282-1293.
29. Leroux A, Ferrere G, Godie V, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 2012; 57: 141-149.
30. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M,. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-579.